Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
130.67
-0.78 (-0.60%)
At close: Apr 28, 2026, 4:00 PM EDT
129.40
-1.27 (-0.97%)
After-hours: Apr 28, 2026, 6:05 PM EDT
Inhibrx Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1.3 | 0.2 | 1.8 | 1.32 | 7.23 | |
| Revenue Growth (YoY) | 550.00% | -88.89% | 36.88% | -81.81% | -43.89% | |
| Cost of Revenue | 113.03 | 177.84 | 191.64 | 101.6 | 71.44 | |
| Gross Profit | -111.73 | -177.64 | -189.84 | -100.29 | -64.21 | |
| Selling, General & Admin | 23.3 | 44.64 | 29.35 | 15.04 | 12.36 | |
| Operating Expenses | 23.3 | 44.64 | 29.35 | 15.04 | 12.36 | |
| Operating Income | -135.03 | -222.29 | -219.19 | -115.32 | -76.56 | |
| Interest Expense | -12.2 | -13.49 | -31.84 | - | - | |
| Interest & Investment Income | 7.55 | 10.94 | 11.92 | - | - | |
| Earnings From Equity Investments | - | - | -1.63 | - | - | |
| Other Non Operating Income (Expenses) | -0.38 | 0.08 | -0.58 | 0 | -5.2 | |
| EBT Excluding Unusual Items | -140.05 | -224.76 | -241.32 | -115.32 | -81.77 | |
| Merger & Restructuring Charges | - | -109.16 | -0.04 | - | - | |
| Other Unusual Items | - | 2,021 | - | - | - | |
| Pretax Income | -140.05 | 1,688 | -241.36 | -115.32 | -81.77 | |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | |
| Net Income | -140.06 | 1,688 | -241.36 | -115.33 | -81.77 | |
| Net Income to Common | -140.06 | 1,688 | -241.36 | -115.33 | -81.77 | |
| Shares Outstanding (Basic) | 15 | 15 | 12 | 40 | 38 | |
| Shares Outstanding (Diluted) | 15 | 15 | 12 | 40 | 38 | |
| Shares Change (YoY) | 3.36% | 27.17% | -70.62% | 5.52% | 50.47% | |
| EPS (Basic) | -9.04 | 114.01 | -20.48 | -2.88 | -2.15 | |
| EPS (Diluted) | -9.04 | 112.62 | -20.48 | -2.88 | -2.15 | |
| Free Cash Flow | -129.83 | -197.01 | -197.9 | -91.5 | - | |
| Free Cash Flow Per Share | -8.38 | -13.15 | -16.80 | -2.28 | - | |
| Operating Margin | -10386.54% | -111143.50% | -12176.94% | -8769.81% | -1058.83% | |
| Profit Margin | -10773.46% | 843786.00% | -13408.94% | -8769.96% | -1130.80% | |
| Free Cash Flow Margin | -9986.54% | -98503.00% | -10994.56% | -6957.95% | - | |
| EBITDA | -132.54 | -220 | -217.99 | -114.1 | - | |
| D&A For EBITDA | 2.48 | 2.29 | 1.19 | 1.23 | - | |
| EBIT | -135.03 | -222.29 | -219.19 | -115.32 | -76.56 | |
| Revenue as Reported | 1.3 | 0.2 | 1.8 | 1.32 | 7.23 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.